Question 1

Who are the top researchers at CureVac (Germany)?

Accepted Answer

Ranked on the quality score, Mariola Fotin‐Mleczek, Benjamin Petsch and Andreas Theß lead among researchers whose main affiliation is CureVac (Germany).

Question 2

What are the most cited papers from CureVac (Germany)?

Accepted Answer

The most cited paper from CureVac (Germany) is "Developing mRNA-vaccine technologies" (Thomas Schlake, Andreas Theß, Mariola Fotin‐Mleczek et al., 2012), with 638 citations. Next come "New Vaccine Technologies to Combat Outbreak Situations" (598) and "Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial" (544).

Question 3

Which research topics does CureVac (Germany) publish most on?

Accepted Answer

By volume in 2022-now: RNA Interference and Gene Delivery, SARS-CoV-2 and COVID-19 Research, Immunotherapy and Immune Responses and Animal Virus Infections Studies.

Question 4

Which keywords describe research at CureVac (Germany)?

Accepted Answer

By fractional works in all years, weighted toward what it does more of than the world: Gene Therapy, Immunity, Gene Silencing, RNA Interference, siRNA Delivery, Vaccine, Cancer Immunotherapy and Innate Immunity.

Question 5

Which fields of science does CureVac (Germany) work in?

Accepted Answer

In all years, 66% of research at CureVac (Germany) is in Life Sciences, 28% in Health Sciences. Its largest fields are Biochemistry, Genetics and Molecular Biology (35%), Medicine (27%), Immunology and Microbiology (26%). It does 3.6× the world's share of Life Sciences.

Question 6

Is CureVac (Germany)'s research output growing?

Accepted Answer

Output in 2022-2025 was 20% higher than in 2018-2021.